[go: up one dir, main page]

MX2008014064A - Derivados radiomarcados de dihidrotetrabenazina y su uso como agentes de diagnostico por imagenes. - Google Patents

Derivados radiomarcados de dihidrotetrabenazina y su uso como agentes de diagnostico por imagenes.

Info

Publication number
MX2008014064A
MX2008014064A MX2008014064A MX2008014064A MX2008014064A MX 2008014064 A MX2008014064 A MX 2008014064A MX 2008014064 A MX2008014064 A MX 2008014064A MX 2008014064 A MX2008014064 A MX 2008014064A MX 2008014064 A MX2008014064 A MX 2008014064A
Authority
MX
Mexico
Prior art keywords
radiolabeled
imaging agents
dihydrotetrabenazine
derivatives
vesicular monoamine
Prior art date
Application number
MX2008014064A
Other languages
English (en)
Inventor
Hank F Kung
Mei-Ping Kung
Michael Kilbourn
Daniel M Skovronsky
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2008014064A publication Critical patent/MX2008014064A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Esta invención se relaciona con un método para el diagnóstico por imágenes de transportadores de monoamina vesiculares con compuestos marcados y composiciones farmacéuticas que los comprenden, y con métodos para preparar compuestos marcados útiles en el diagnóstico por imágenes de transportadores de monoamina vesiculares. Esta invención también se relaciona con compuestos y con métodos para monitorear el progreso de una enfermedad relacionada con los transportadores de monoamina vesiculares.
MX2008014064A 2006-05-02 2007-05-01 Derivados radiomarcados de dihidrotetrabenazina y su uso como agentes de diagnostico por imagenes. MX2008014064A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79651806P 2006-05-02 2006-05-02
US90811607P 2007-03-26 2007-03-26
PCT/US2007/010478 WO2007130365A2 (en) 2006-05-02 2007-05-01 Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents

Publications (1)

Publication Number Publication Date
MX2008014064A true MX2008014064A (es) 2009-06-12

Family

ID=38668238

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008014064A MX2008014064A (es) 2006-05-02 2007-05-01 Derivados radiomarcados de dihidrotetrabenazina y su uso como agentes de diagnostico por imagenes.

Country Status (19)

Country Link
US (1) US8562949B2 (es)
EP (2) EP2604290A3 (es)
JP (1) JP5392622B2 (es)
KR (1) KR101429302B1 (es)
CN (1) CN101484190B (es)
AU (1) AU2007248764B2 (es)
BR (1) BRPI0711481A8 (es)
CA (1) CA2650904C (es)
DK (1) DK2012833T3 (es)
ES (1) ES2525932T3 (es)
IL (1) IL195044A (es)
MX (1) MX2008014064A (es)
NO (1) NO341065B1 (es)
PL (1) PL2012833T3 (es)
PT (1) PT2012833E (es)
SI (1) SI2012833T1 (es)
TW (1) TWI432214B (es)
WO (1) WO2007130365A2 (es)
ZA (1) ZA200810200B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008500B2 (en) 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
US7897770B2 (en) 2007-10-25 2011-03-01 General Electric Company Fluorinated dihydrotetrabenazine ether imaging agents and probes
WO2009055520A2 (en) * 2007-10-25 2009-04-30 General Electric Company Fluorinated dihydrotetrabenazine ether imaging agents and probes
US7897769B2 (en) 2007-10-25 2011-03-01 General Electric Company Intermediates for fluorinated dihydrotetrabenazine ether imaging agents and probes
CA2703563A1 (en) * 2007-10-31 2009-05-07 Alseres Pharmaceuticals, Inc. Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
US7902364B2 (en) 2007-11-29 2011-03-08 General Electric Company Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US8053578B2 (en) * 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
US7910738B2 (en) 2007-11-29 2011-03-22 General Electric Company Intermediates for alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US7919622B2 (en) 2007-12-07 2011-04-05 Kande Kankanamalage Dayarathna Amarasinghe Intermediates for fluorinated tetrabenazine carbinol compounds imaging agents and probes
US8013161B1 (en) 2007-12-07 2011-09-06 General Electric Company Fluoroalkyl tetrabenazine carbinol compounds as imaging agents and probes
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
CA2972242A1 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
KR20110074614A (ko) * 2009-03-19 2011-06-30 고쿠리츠 다이가쿠 호진 교토 다이가쿠 췌도 이미징용 분자 프로브 전구체 및 그 사용
CN102120742B (zh) * 2010-01-08 2013-03-13 中国药科大学 一种丁苯那嗪的制备方法
EP2394668A1 (en) * 2010-06-01 2011-12-14 Julius-Maximilians-Universität Würzburg PET radiopharmaceuticals for differential diagnosis between bilateral and unilateral conditions of primary hyperaldosteronism
CN104744456A (zh) 2010-06-01 2015-07-01 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
CN101985446B (zh) * 2010-06-10 2012-05-30 江苏省原子医学研究所 一种(±)-9-O-去甲基-α-二氢丁苯那嗪合成方法
WO2012121746A2 (en) * 2011-03-09 2012-09-13 The General Hospital Corporation Imaging beta cell mass
CN102260255B (zh) * 2011-07-07 2013-07-10 江苏省原子医学研究所 一种9,10-二甲氧基-1,3,4,6,7,11b-六氢-3-异丁基-2H-苯并[a]喹嗪-2-酮的简便合成方法
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
HK1212232A1 (en) 2012-09-18 2016-06-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN102936246A (zh) * 2012-11-08 2013-02-20 江苏暨明医药科技有限公司 丁苯那嗪的合成方法
AU2014212586A1 (en) 2013-01-31 2015-08-06 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of VMAT2
EP3049087A4 (en) * 2013-09-27 2017-05-24 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2015077521A1 (en) * 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
HK1224294A1 (zh) * 2013-11-22 2017-08-18 Auspex Pharmaceuticals, Inc. 治疗异常肌肉活动的方法
NZ720301A (en) 2013-12-03 2022-01-28 Auspex Pharmaceuticals Inc Deuterated tetrabenazine compounds
US20160346270A1 (en) 2014-01-27 2016-12-01 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EA201691582A1 (ru) 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
SG11201706959TA (en) 2015-03-06 2017-09-28 Auspex Pharmaceuticals Inc Methods for the treatment of abnormal involuntary movement disorders
BR112018007118A2 (pt) 2015-10-09 2018-12-11 Teva Pharmaceuticals Int Gmbh método para tratar um distúrbio de deficiência de dopamina, método para melhorar o tempo motor ativo sem discinesia num paciente com doença de parkinson, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir o tempo motor inativo num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir flutuações de nível de dopamina estriatal num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina após um tratamento de longo prazo, composição farmacêutica e embalagem
TW201906818A (zh) 2017-05-31 2019-02-16 美商５１１製藥公司 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
CN108912118A (zh) * 2018-07-12 2018-11-30 新乡学院 一种四氢异喹啉并三嗪骨架化合物及其制备方法
WO2021027792A1 (zh) * 2019-08-12 2021-02-18 山东绿叶制药有限公司 Vmat2抑制剂及其制备方法和应用
CN111320620A (zh) * 2020-03-17 2020-06-23 四川大学华西医院 一种异喹啉并哒嗪酮类化合物及其合成方法和应用
CR20230448A (es) 2021-03-22 2023-10-27 Neurocrine Biosciences Inc Inhibidores de vmat2 y métodos de uso
CN114288419B (zh) * 2021-12-30 2023-08-18 中山大学附属第八医院（深圳福田） 一种利福平纳米递药系统的制备及其在防治帕金森病方面的应用
CN115536705B (zh) * 2022-09-23 2024-09-06 江苏省原子医学研究所 靶向ii型囊泡单胺转运体分子探针及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3053845A (en) 1962-09-11 Benzofykedocolines
DE1470074C3 (de) * 1964-07-25 1974-01-24 Merck Patent Gmbh, 6100 Darmstadt 1,2,3,4,6,7-Hexahydro-l lbH-benzo eckige Klammer auf a eckige Klammer zu chinolizine sowie deren Acetate und/oder phsiologisch verträgliche Säureadditionssalze sowie Verfahren zu ihrer Herstellung
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US5278308A (en) * 1992-02-28 1994-01-11 The Trustees Of The University Of Pennsylvania Iodine derivatives of tetrabenazine
FR2770215B1 (fr) 1997-10-28 2000-01-14 Pf Medicament Derives d'aminomethyl-benzo[a]quinolizidine, leur preparation et leur application en therapeutique pour les maladies neurodegeneratives
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
CN101484190A (zh) 2009-07-15
KR101429302B1 (ko) 2014-08-11
US20080050312A1 (en) 2008-02-28
ZA200810200B (en) 2012-02-29
BRPI0711481A2 (pt) 2011-11-16
IL195044A (en) 2013-08-29
CA2650904A1 (en) 2007-11-15
JP5392622B2 (ja) 2014-01-22
TW200810783A (en) 2008-03-01
CN101484190B (zh) 2011-07-20
EP2604290A3 (en) 2013-07-10
EP2604290A2 (en) 2013-06-19
EP2012833A4 (en) 2011-06-29
DK2012833T3 (en) 2015-01-19
ES2525932T3 (es) 2015-01-02
IL195044A0 (en) 2011-08-01
WO2007130365A3 (en) 2008-11-27
SI2012833T1 (sl) 2015-03-31
EP2012833B1 (en) 2014-10-29
TWI432214B (zh) 2014-04-01
NO341065B1 (no) 2017-08-14
US8562949B2 (en) 2013-10-22
CA2650904C (en) 2015-07-07
NO20085004L (no) 2009-02-02
PL2012833T3 (pl) 2015-05-29
AU2007248764B2 (en) 2013-08-01
KR20090007781A (ko) 2009-01-20
BRPI0711481A8 (pt) 2017-11-28
WO2007130365A2 (en) 2007-11-15
JP2009535403A (ja) 2009-10-01
EP2012833A2 (en) 2009-01-14
AU2007248764A1 (en) 2007-11-15
PT2012833E (pt) 2014-12-23

Similar Documents

Publication Publication Date Title
MX2008014064A (es) Derivados radiomarcados de dihidrotetrabenazina y su uso como agentes de diagnostico por imagenes.
NO2018030I1 (no) Florbetapir (18F)
MY153198A (en) Inhibitors of protein aggregation
SMT201800067T1 (it) Derivati deuterati di benzochinolizina come inibitori del trasportatore vescicolare di monoammine 2
MY163516A (en) Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
IL188786A0 (en) Intermediate compound for synthesizing pharmaceutical agent and production method thereof
TN2009000063A1 (en) Compounds and methods for 18f labeled agents
DE602006019654D1 (de) Zusammensetzung enthalten wasserlösliche diätetische Faser und Verfahren für ihre Herstellung
EP1937766A4 (en) MODIFIED POLYAMIDES, USES THEREOF AND MANUFACTURING METHOD THEREFOR
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
TN2009000100A1 (en) Silicon derivatives for pet imaging
IL189961A0 (en) Novel benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use in particular as c-met inhibitors
ATE490958T1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
ZA200803116B (en) Novel indole-containing beta agonists, method for producing them and their use as drugs
HUP0500921A2 (en) Tetrazole derivatives, process for their preparation and their use
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
MX2010001075A (es) Derivados de n-piperidin-4-ilmetil-amida y su uso como inhibidores de recaptacion del neurotransmisor de monoamina.
TN2009000233A1 (en) Radiolabelling via fluorination of aziridines
IL199254A (en) Derivatives of Aminoguanidine, Pharmaceuticals Containing Them, Process of Preparing and Using Them
MX2009005804A (es) Composicion farmaceutica de memantina.
MX2011012602A (es) Proceso para la preparacion de un agente de yodatacion.
CY1115968T1 (el) Ραδιοεπισημασμενα παραγωγα διυδροτραβεναζινης και χρηση αυτων ως παραγοντες απεικονισης
EA200701903A1 (ru) Способ получения быстрорастворимого порошка имидаприла
DE102006033187A8 (de) Pulverförmiges Gelatineprodukt und Verfahren zu dessen Herstellung

Legal Events

Date Code Title Description
FG Grant or registration